Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

IntroductionTwo doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be improved by a third dose in adults. The use of a third dose of CoronaVac in adolescents may be supported by immunobridgi...

Full description

Bibliographic Details
Main Authors: Daniel Leung, Carolyn A. Cohen, Xiaofeng Mu, Jaime S. Rosa Duque, Samuel M. S. Cheng, Xiwei Wang, Manni Wang, Wenyue Zhang, Yanmei Zhang, Issan Y. S. Tam, Jennifer H. Y. Lam, Sau Man Chan, Sara Chaothai, Kelvin K. H. Kwan, Karl C. K. Chan, John K. C. Li, Leo L. H. Luk, Leo C. H. Tsang, Nym Coco Chu, Wilfred H. S. Wong, Masashi Mori, Wing Hang Leung, Sophie Valkenburg, Malik Peiris, Wenwei Tu, Yu Lung Lau
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
COVID-19
vaccine
CoronaVac
Omicron
adolescent
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1106837/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1106837/full

Similar Items